100 related articles for article (PubMed ID: 15330682)
1. Extended-release metformin hydrochloride. Single-composition osmotic tablet formulation.
Wagstaff AJ; Figgitt DP
Treat Endocrinol; 2004; 3(5):327-32. PubMed ID: 15330682
[TBL] [Abstract][Full Text] [Related]
2. Metformin extended release: metformin gastric retention, metformin GR, metformin XR.
Drugs R D; 2005; 6(5):316-9. PubMed ID: 16128603
[TBL] [Abstract][Full Text] [Related]
3. Steady-state pharmacokinetics of a novel extended-release metformin formulation.
Timmins P; Donahue S; Meeker J; Marathe P
Clin Pharmacokinet; 2005; 44(7):721-9. PubMed ID: 15966755
[TBL] [Abstract][Full Text] [Related]
4. Metformin extended release--DepoMed: metformin, metformin gastric retention, metformin GR.
Drugs R D; 2004; 5(4):231-3. PubMed ID: 15230631
[TBL] [Abstract][Full Text] [Related]
5. Clinical development of metformin extended-release tablets for type 2 diabetes: an overview.
Schwartz SL; Gordi T; Hou E; Cramer M; Heritier M; Cowles VE
Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1235-43. PubMed ID: 18721117
[TBL] [Abstract][Full Text] [Related]
6. Metformin extended release for the treatment of type 2 diabetes mellitus.
Schwartz SL; Wu JF; Berner B
Expert Opin Pharmacother; 2006 Apr; 7(6):803-9. PubMed ID: 16556094
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of once- or twice-daily extended release metformin compared with thrice-daily immediate release metformin in type 2 diabetes mellitus.
Bhansali A; Masoodi SR
J Assoc Physicians India; 2005 May; 53():441-5. PubMed ID: 16124352
[TBL] [Abstract][Full Text] [Related]
8. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
9. Controlled release of metformin hydrochloride and repaglinide from sandwiched osmotic pump tablet.
Qin C; He W; Zhu C; Wu M; Jin Z; Zhang Q; Wang G; Yin L
Int J Pharm; 2014 May; 466(1-2):276-85. PubMed ID: 24607209
[TBL] [Abstract][Full Text] [Related]
10. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
Swanson JM; Wigal SB; Wigal T; Sonuga-Barke E; Greenhill LL; Biederman J; Kollins S; Nguyen AS; DeCory HH; Hirshe Dirksen SJ; Hatch SJ;
Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578
[TBL] [Abstract][Full Text] [Related]
11. Epidemiologic Surveillance of Glycemic Response to a Scored, Breakable, Extended Release, Fixed Dose Combination of Gliclazide and Metformin in Persons with Type 2 Diabetes.
Kalra S; Das AK
J Assoc Physicians India; 2017 Jun; 65(6):38-41. PubMed ID: 28782312
[TBL] [Abstract][Full Text] [Related]
12. Dose Comparison And Side Effect Profile Of Metformin Extended Release Versus Metformin Immediate Release.
Hameed M; Khan K; Salman S; Mehmood N
J Ayub Med Coll Abbottabad; 2017; 29(2):225-229. PubMed ID: 28718236
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and tolerability of extended-release clarithromycin.
Guay DR; Gustavson LE; Devcich KJ; Zhang J; Cao G; Olson CA
Clin Ther; 2001 Apr; 23(4):566-77. PubMed ID: 11354390
[TBL] [Abstract][Full Text] [Related]
14. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.
Barnett AH; Charbonnel B; Donovan M; Fleming D; Chen R
Curr Med Res Opin; 2012 Apr; 28(4):513-23. PubMed ID: 22313154
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers.
Kim BH; Shin KH; Kim J; Lim KS; Kim KP; Kim JR; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Ther; 2009 Nov; 31(11):2755-64. PubMed ID: 20110017
[TBL] [Abstract][Full Text] [Related]
16. Inlay osmotic pump tablets containing metformin and glipizide.
Patel RB; Patel GN; Patel HR; Patel MM
Drug Dev Ind Pharm; 2011 Oct; 37(10):1244-52. PubMed ID: 21466414
[TBL] [Abstract][Full Text] [Related]
17. Advantages of extended-release metformin in patients with type 2 diabetes mellitus.
Jabbour S; Ziring B
Postgrad Med; 2011 Jan; 123(1):15-23. PubMed ID: 21293080
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of metformin gastric-retentive tablets in healthy volunteers.
Gusler G; Gorsline J; Levy G; Zhang SZ; Weston IE; Naret D; Berner B
J Clin Pharmacol; 2001 Jun; 41(6):655-61. PubMed ID: 11402634
[TBL] [Abstract][Full Text] [Related]
19. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
Jenner P; Könen-Bergmann M; Schepers C; Haertter S
Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
